Boehringer Ingelheim Pharmaceuticals, Inc. has recalled 998 bottles of Synjardy (empagliflozin and metformin hydrochloride) 5 mg/1000 mg tablets. This prescription medication, used to treat type 2 diabetes, is being recalled due to the potential for cross-contamination with other products during the manufacturing process. Consumers should immediately check their prescription bottles to see if they have the affected lot and contact their healthcare provider to discuss alternative treatment while the product is returned.
The tablets may have been contaminated with other medicinal products during manufacturing. This poses a risk of unintended exposure to secondary medications, which could cause adverse drug reactions or interfere with the effectiveness of the diabetes treatment.
Healthcare consultation and pharmacy return
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.